Neither Selank nor Semax is an FDA-approved drug in the United States. Every clinical claim below links to a primary source.
Two peptides get lumped together constantly. Same country of origin, same murky US regulatory status, same vendor lists. That is not the same as saying they do the same thing. Before comparing them on anything, it helps to fix the criteria first and then apply them, rather than let vibes decide. Below are five fields: lineage, mechanism, human evidence, regulatory standing, and acquisition channel. Selank and Semax get scored on each, one at a time.
One constraint applies to both entries before scoring even starts, so it is stated once here rather than repeated five times: most of the human evidence for either peptide is Russian-language, dated, and unreplicated in large independent Western trials. That is a shared ceiling, not a tiebreaker. Nothing below should be read as clearing that bar. It is a comparison within a low-evidence category, not a claim that either compound has robust proof behind it.
Criterion 1: Lineage and stated purpose
Selank. A synthetic heptapeptide built from a fragment of tuftsin, a naturally occurring immune peptide. Developed at a Russian research institute, used there as a prescription anxiety medication. Its research file is organized around anxiety, with immune modulation as a secondary interest. The strongest human data point on file is a 2008 trial pitting Selank against the benzodiazepine medazepam in 62 patients with generalized anxiety disorder and neurasthenia, reporting broadly comparable anxiety outcomes plus some added anti-asthenic effect for Selank [S1]. A second, smaller study tracked immune markers in patients with anxiety-asthenic disorders [S2].
Semax. A synthetic peptide built from a fragment of adrenocorticotropic hormone, specifically ACTH(4-10), modified for stability. Developed at a different Russian academic institute, registered there for use around ischemic stroke and cognitive or neurological conditions. Its file is organized around neuroprotection and cognition, not anxiety. Most of what shows up in Western databases is preclinical: rodent cerebral ischemia models where Semax has been reported to affect neurotrophic signaling and shift expression of inflammation- and neurotransmitter-related genes [S4]. As with Selank, the human clinical record sits mostly in Russian-language sources rather than large Western trials.
Field verdict: different parent molecules, different intended jobs. This is the criterion that explains most of what follows, and it is not close.
Criterion 2: Mechanism plausibility
Selank. A 2018 receptor-binding study described Selank as a positive allosteric modulator at GABA receptors, the same broad receptor family classic anxiolytics work on, and noted it can interfere with how benzodiazepines like diazepam act on those receptors [S3]. That is a mechanism consistent with an anxiety story. It is not, however, uncontested: other in-vitro work found no direct effect from Selank alone on the GABA-signaling genes tested. Call this mechanism plausible and still disputed, not settled.
Semax. The preclinical literature centers on brain-derived neurotrophic factor and nerve growth factor signaling, along with altered gene expression tied to inflammation and neurotransmission in ischemia models [S4]. One distinguishing note: despite deriving from an ACTH fragment, Semax is not reported to trigger the adrenal steroid cascade that full ACTH would. The mechanism story here is brain protection and signaling, not anxiety relief.
Field verdict: the two mechanisms point in the same directions their lineages suggest. Selank toward calming/anxiety circuitry, Semax toward neurotrophic/neuroprotective circuitry. Neither is proof of a felt clinical effect. Both lean more on preclinical and small, non-Western human data than most marketing copy lets on.
Criterion 3: Human evidence quality
Selank. One head-to-head human trial against an active comparator (medazepam, n=62) [S1], plus one small human study on immune markers [S2]. Thin, and unreplicated outside Russian-language literature, but it exists and is aimed at anxiety, the outcome in question.
Semax. The citable strength here is a 2021 rat ischemia-reperfusion study on protein expression [S4], which is preclinical, not human. The comparison is not flattering on this specific criterion: Selank has an actual human trial on the books for its target claim; the Semax evidence cited here does not reach that bar.
Field verdict: Selank scores higher specifically on “has a human trial pointed at its own primary claim.” Semax’s stronger showing is mechanistic and animal-model, not clinical-human. This does not make Semax’s overall case weaker in general, just weaker on this one line item.
Criterion 4: Regulatory standing
Both compounds are unapproved as drugs in the United States. Both have been sitting inside the FDA’s ongoing review of substances nominated for pharmacy compounding, a list under active review for several peptides as of 2026 [S5]. That means the specific compounding status of each should be checked against the FDA’s own current pages rather than assumed from an article, including this one.
Field verdict: tied. No separation here; check the source before acting on either.
Criterion 5: Acquisition channel
This is the criterion that actually decides outcomes, more than the first four combined.
Channel one: the gray peptide-vial trade. A buyer orders either compound labeled “not for human consumption.” No clinician reviewed the order, no prescription exists, no pharmacy touched it, nobody checks in afterward, and nothing about strength, identity, or purity was verified by a regulator.
Channel two: supervised medicine. A licensed clinician evaluates the person and the goal first. A prescription follows only if it fits. The product comes from a licensed compounding pharmacy instead of an unmarked shipping label. A telehealth provider such as FormBlends runs on this sequence, named here to illustrate what the supervised tier looks like, not as an endorsement to purchase anything, and there is nothing for sale in this article.
Field verdict: the peptide-versus-peptide question is, in practical terms, the smaller of the two decisions a buyer makes. Getting the Selank-versus-Semax call right while sourcing either through an unverified vial still leaves the larger risk unmanaged.
Scorecard summary
| Goal | Evidence leans toward | Basis |
|---|---|---|
| Anxiety reduction | Selank | Human trial vs medazepam [S1], GABA-modulation mechanism [S3] |
| Cognition / neuroprotection | Semax | Neurotrophic/neuroprotective mechanism in ischemia models [S4] |
| General wellness, energy, “brain optimization” | Neither | No human evidence cited for either compound on these targets |
| Regulatory clarity | Tie | Both unapproved, both under FDA compounding review as of 2026 [S5] |
| Acquisition safety | Depends on channel, not compound | Supervised clinician + licensed pharmacy vs unverified vial |
Bottom line
Selank and Semax are not two versions of the same product. Selank comes from a tuftsin fragment, was built for anxiety, and has one small human trial to show for it. Semax comes from an ACTH fragment, was built for neuroprotection and cognition, and has its strongest support in rodent studies rather than human trials. On an anxiety goal, the scorecard favors Selank. On a cognitive or neuroprotective goal, it favors Semax. On vague wellness goals, neither compound clears the bar, and picking between them there is choosing between two underpowered options. Both share the same regulatory limbo and the same thin, largely Russian-language evidence base. And for both, the criterion that actually predicts what a buyer ends up with is not the peptide name on the label, it is whether a licensed clinician and a licensed pharmacy are anywhere in the chain.
Frequently Asked Questions
Are Selank and Semax the same peptide? No. They get filed together because of a shared Russian research origin, similar US regulatory ambiguity, and overlapping vendor lists, but the molecules and their intended jobs differ. Selank derives from tuftsin and was built for anxiety. Semax derives from ACTH(4-10) and was built for neuroprotection and cognition.
Which one scores better for anxiety? Selank, on the evidence available. Its 2008 trial against medazepam in 62 patients [S1] and its proposed GABA-receptor mechanism [S3] are both aimed at anxiety specifically. The evidence base is small and unreplicated in Western trials, but it is at least pointed at the right target, which is not true of Semax.
Which one scores better for cognition or focus? Semax, on lineage and mechanism. Its research tradition was built around neuroprotection, with support drawn mostly from neurotrophic pathway studies in animal ischemia models [S4]. That is preclinical evidence, not proof of a cognitive benefit in humans, so treat “aimed at cognition” and “proven for cognition” as two separate claims.
Are either of these FDA approved? No. Neither is an approved drug in the United States. Both have moved through the FDA’s review process for substances nominated for pharmacy compounding, a list under active review for multiple peptides in 2026 [S5]. Check the FDA’s current pages for the up-to-date status of each, since these lists move.
Does stacking Selank and Semax make sense? There is no robust human data on combining the two. The more useful question is not whether the pairing works but whether a licensed clinician and licensed pharmacy are involved in sourcing either one on its own.
What’s the single decision that matters most here? The channel, not the peptide. Both compounds are available either as unverified gray-market vials with no clinician or pharmacy attached, or through a supervised medical pathway with a prescriber reviewing the individual case. Getting the peptide choice right and the sourcing choice wrong is still a bad outcome.
Quick facts on Selank specifically
What is Selank and where does it come from? Selank is a synthetic heptapeptide developed in Russia at the Institute of Molecular Genetics, built from a fragment of the human protein tuftsin. Russian regulators approved it there as an anxiolytic nasal spray decades ago. It carries no approved status in the US, EU, or most Western countries. It has an actual pharmacological history behind it, not an invented supplement story.
What does Selank do mechanistically? The leading hypothesis is GABAergic modulation combined with an effect on BDNF levels, together proposed to explain a calming, mildly stimulating profile without benzodiazepine-style sedation. Most of this comes from Russian-language trials with limited independent replication, so the mechanism picture remains unsettled rather than confirmed.
Is Selank legal to buy in the United States? It sits in a gray zone. It is not a scheduled controlled substance, but the FDA has not approved it, so selling it as a drug or supplement for human use is not lawful. Some buyers get it through compounding pharmacies operating under physician supervision, such as FormBlends, which is the more accountable route. Research-chemical vendors offer no such accountability on purity or dosing.
What side effects show up in the record? The most commonly reported effects are mild: nasal irritation from the spray delivery, brief fatigue, occasional mild headache. Serious adverse events are not prominently documented, but that record comes mostly from supervised clinical settings with limited overall evidence. Self-administering an unregulated peptide outside medical oversight means operating with less safety data than an approved drug would carry.
References
- Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008. Russian-language human trial, 62 patients, Selank vs medazepam. https://pubmed.ncbi.nlm.nih.gov/18454096/
- Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008. Russian-language human study of immune markers. https://pubmed.ncbi.nlm.nih.gov/18577961/
- Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein & Peptide Letters, 2018. Reports Selank as a positive allosteric modulator at GABA receptors that can interfere with benzodiazepine modulation.
- Medvedeva EV, Dmitrieva VG, Limborska SA, et al. Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion. International Journal of Molecular Sciences, 2021. Preclinical rat ischemia model; Semax effects on neuroprotective and gene-expression pathways.
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding (reference list of nominated substances, includes peptide entries).
